Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CNS Pharmaceuticals, Inc. - Common Stock (NQ:CNSP)

1.250 -0.040 (-3.10%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CNS Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Israeli Company Seeks to Develop Micro-Robots to Boost Precision Medicine
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Distinguished with Unique Capabilities
Via Investor Brand Network
Exposures COVID-19
CNS Pharma's Lead Drug Candidate Crosses The Blood Brain Barrier - What Does That Mean? Watch the full show here!
Watch the full show here! John Climaco, Chairman & CEO of CNS Pharmaceuticals (NASDAQ: CNSP) presented at Benzinga’s webinar: Pharma Companies Vs. A Tough Macro Backdrop. 
Via Benzinga
Researchers Unlock Previously Unknown Weakness of Brain Cancer
Via Investor Brand Network
CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference
Via ACCESSWIRE
Researchers Trace Glioma Brain Tumor Origins to Epigenome
Via Investor Brand Network
CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series
Via ACCESSWIRE
CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports on Berubicin Pivotal Study, Announces Participation in Biotech Conference
Via Investor Brand Network
CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract Selected for Poster Presentation at 2023 SNO/ASCO CNS Cancer Conference
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference
Via ACCESSWIRE
Clinical Trial Testing Modified Viruses as Brain Cancer Treatment Begins
Via Investor Brand Network
National GBM Awareness Events Underscore Significance of Clinical Trial Progress for CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
Via Investor Brand Network
Doctors Use Melanoma Drugs to Shrink Brain Tumors by 90% in Small Study
Via Investor Brand Network
Harvard Scientists Create AI Tool to Provide Real-Time Genetic Analysis of Brain Cancer During Surgery
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
Biochemist Working to Make Chemo Sans Side Effects
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in July’s Virtual Investor Summer Spotlight Series
Via Investor Brand Network
Immunotherapy Implants Could Turn Tumor Cells on Each Other
Via Investor Brand Network
Virus Therapy Plus Radiation Could Improve Brain Tumor Treatment, Study Finds
Via Investor Brand Network
Experimental Vaccine Brings Hope of Slowing Glioblastoma Tumor Regrowth
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation in Upcoming Maxim Group Virtual Healthcare Conference
Via Investor Brand Network
Researchers Explain How Brain Cancers Hijack Neural Circuits
Via Investor Brand Network
Scientists Create Open-Source Platform to Analyze Brain Tumors in Kids
Via Investor Brand Network
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:GILD),(NASDAQ:RAIN),(NASDAQ:CNSP),(NYSE:BMY) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
Study Shows Brain Cancer Among Top Cancer Types in US
Via Investor Brand Network
Proton Beam Therapy Could Boost Quality of Life for Cancer Patients
Via Investor Brand Network
Topics Death
Exposures Death
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Achieves 50%+ Enrollment in Potentially Pivotal Berubicin Study
Via Investor Brand Network
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.